| Vyant Bio is a biotechnology company reinventing drug discovery for neurodevelopmental and neurodegenerative disorders. Co.'s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Co.'s platform is designed to: elucidate disease pathophysiology; formulate therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers; and guide clinical trial patient selection and trial design. Co.'s programs are focused on identifying small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders and Parkinson's Disease. The VYNT YTD return is shown above.
The YTD Return on the VYNT YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether VYNT YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VYNT YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.